ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pacira BioSciences and Alcon side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Pacira BioSciencesAlcon
studies on the registry102719
open to participants now39
phase 3 studies under way12
reach primary completion within a year39
programswith a study of their own in two years22

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePacira BioSciencesAlcon
Phase 100%00%
Phase 2

Pacira BioSciences: 1 of its 2 programs at phase 2

  1. enekinragene inzadenovecphase 2
50%
00%
Phase 3

Pacira BioSciences: 1 of its 2 programs at phase 3

  1. Triamcinolone Acetonidephase 3
50%

Alcon: 1 of its 2 programs at phase 3

  1. Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Freephase 3
50%
Approved, new studies00%

Alcon: 1 of its 2 programs at approved, new studies

  1. netarsudilapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pacira BioSciences2 readouts · 1 phase 3

Pacira BioSciences, Nov ’26: 1 program whose next study reaches primary completion

  1. enekinragene inzadenovecphase 2 · Nov 0 · NCT06884865

Pacira BioSciences, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Triamcinolone Acetonidephase 3 · Dec 0 · NCT06269705
··········
Alcon1 readouts · 1 phase 3

Alcon, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Freephase 3 · Nov 0 · NCT07578363
···········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pacira BioSciences

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Alcon

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Pacira BioSciences 1 of 2 · Alcon 1 of 2 programs (2 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.